Novel Inhibitors of Carboxypeptidase G<sub>2</sub> (CPG<sub>2</sub>):  Potential Use in Antibody-Directed Enzyme Prodrug Therapy

Tariq H Khan, Ebun Eno‐Amooquaye, F Searle, Pat J. Browne, Helen M. I. Osborn, Philip J. Burke

Journal of Medicinal Chemistry · 1999 · 21 citations · 17 references

DOIFull text

Open access

Concepts

Abstract

The design and synthesis of potent thiocarbamate inhibitors for carboxypeptidase G2 are described. The best thiocarbamate inhibitor N-(p-methoxybenzenethiocarbonyl)amino-L-glutamic acid 6d, chosen for preliminary investigations of in vitro antibody-directed enzyme prodrug therapy (ADEPT), abrogated the cytotoxicity of a combination of A5B7-carboxypeptidase G2 conjugate and prodrug PGP (N-p-{N,N-bis (2-chloroethyl)amino}phenoxycarbonyl-L-glutamate) toward LS174T cells. This is the first report of a small-molecule enzyme inhibitor proposed for use in conjunction with the ADEPT approach.

References

17